Quarterly Psychedelics Briefing: Q2 2026
Welcome to our Q2 2026 Quarterly Briefing.
Every three months, our Founder & Editor Josh Hardman walks you through major developments from the prior quarter across drug development, policy and regulation, science and academia, and much more. He closes with a look ahead to the next quarter, so you know what to look out for.
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In